To discuss specific biomarkers beyond clinical staging that may predict treatment outcomes in head and neck cancer, including PDL-1, nutritional indexes, and integrin alpha genes.
Key Findings:
PDL-1 scores can predict response to immunotherapy in recurrent/metastatic nasopharyngeal cancer, as shown in a meta-analysis.
The systemic immune inflammation nutrition score demonstrated predictive value for overall survival in a large cohort study.
Low PNI is associated with worse survival outcomes across treatment modalities, indicating its prognostic significance.
High expression of ITGA3, ITGA5, and ITGA6 correlates with poor prognosis in HNSCC, suggesting their potential as prognostic biomarkers.
Interpretation:
Biomarkers such as nutritional indexes and PDL-1 scores are crucial for predicting treatment outcomes in head and neck cancer, emphasizing the need for a multipronged approach that integrates various biomarker types.
Limitations:
The systemic immune inflammation nutrition score was based on a single time point, limiting its applicability over time.
The reproducibility and external validation of nomograms require further prospective studies to confirm their utility in clinical settings.
Conclusion:
The integration of various biomarkers, including PDL-1, nutritional indexes, and integrin alpha genes, is essential for improving treatment selection and individualization in head and neck cancer.
